What is the recommended management for an obstructive gastric lesion causing persistent nausea, vomiting, early satiety, or inability to tolerate oral intake?

Management of Obstructive Gastric Lesions

For patients with gastric outlet obstruction causing persistent nausea, vomiting, early satiety, or inability to tolerate oral intake, the management approach depends critically on life expectancy and surgical candidacy: surgical gastrojejunostomy (preferably laparoscopic) should be performed in patients with life expectancy >2 months who are surgically fit, while enteral stent placement is recommended for those who are not surgical candidates. 1

Algorithm for Management Decision-Making

Step 1: Assess Surgical Candidacy and Prognosis

• Life expectancy >2 months AND good functional status AND surgically fit → Proceed to surgical gastrojejunostomy
• Poor surgical candidate OR limited life expectancy → Consider endoscopic interventions

Step 2: Surgical Approach (When Indicated)

Laparoscopic gastrojejunostomy is strongly preferred over open surgery due to lower blood loss and shorter hospital stay 1. This provides durable symptom relief with lower reintervention rates compared to stenting 2, 3.

Step 3: Endoscopic Management (Non-Surgical Candidates)

Primary Options:

1. Enteral stent placement (SEMS) - First-line endoscopic option 1
2. EUS-guided gastroenterostomy - Acceptable alternative if expertise available 1

Critical Contraindications to Stenting:

• Do NOT use enteral stents in patients with:
  • Multiple luminal obstructions
  • Severely impaired gastric motility
• In these cases, place a venting gastrostomy instead 1

Step 4: Stent Selection (If Stenting Chosen)

For esophageal/gastric cardia obstruction requiring stenting, use fully covered or partially covered SEMS (NOT uncovered), with consideration of stent-anchoring/fixation methods to prevent migration 1.

Important Clinical Nuances

EUS-Guided Gastroenterostomy

This emerging technique combines the minimally invasive nature of stenting with the durability of surgical gastrojejunostomy 4, 2, 3. However:

• Requires specialized expertise and facilities
• No dedicated FDA-approved devices currently available 1
• Technically demanding procedure
• Should only be performed by experienced endoscopists

Pitfalls to Avoid

1. Missing structural causes: Always exclude anatomic abnormalities (gastric volvulus, Roux-en-O configuration post-RYGB) before attributing symptoms to functional disorders 5. These can mimic gastroparesis but require surgical correction.

2. Inappropriate stent placement: Stenting patients with multiple obstructions or poor gastric motility leads to treatment failure and unnecessary procedures 1.

3. Uncovered stents: These have higher rates of tumor ingrowth and complications; always use covered or partially covered stents 1.

4. Underestimating prognosis: Patients with >2 months life expectancy benefit more from surgery than stenting due to lower reintervention rates 1, 6.

Evidence Quality Considerations

The 2021 AGA Clinical Practice Update 1 provides the most comprehensive guideline-based framework for malignant alimentary tract obstruction management. The recommendations are based on systematic review of surgical and endoscopic literature, with clear delineation between bridge-to-surgery and palliative scenarios.

Recent research 4, 2, 3 supports EUS-guided gastroenterostomy as an emerging option, though guideline adoption remains cautious given the lack of FDA-approved dedicated devices and need for specialized expertise.